- Home
- About
- Section Advisors
- Meet Our Field Medical Affairs Team
- Speakers Bureau
- Supporting Organizations
- Contact Us
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Infographics
- Learning Tracks
- Podcasts
- Shareable/Downloadable Content
- Videos
- PsychUSim
- PsychU Roleplay
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Psychiatric Scales
- Psychopharmacology
- Supporting Organizations
Virtual Event – Agitation Associated With Alzheimer’s Dementia (AAD) In The Long-Term Care (LTC) Setting
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Virtual Event – Agitation Associated With Alzheimer’s Dementia (AAD) In The Long-Term Care (LTC) Setting
This review highlights important aspects of agitation associated with Alzheimer’s Dementia (AAD) with a focus on those who are living with this condition or who are caring for those who live with this condition in the Long-Term Care (LTC) setting. This information is intended to help provide a better understanding of the implications of this disorder that are associated with it in the LTC environment including prevalence, medication use, costs of care and the challenges associated with antipsychotic use. It also describes the diagnostic criteria for AAD and explores the potential pathobiological correlations in AAD.
Objectives:
- Learn about agitation associated with Alzheimer’s Dementia (AAD) as a highly prevalent disorder that is present in all stages and severities for those with Alzheimer’s dementia
- Gain understanding about the potential pathobiological elements, and the associated neurotransmitters implicated with AAD
- Review information related to patient and care-giver burden as well as the healthcare utilization and costs associated with AAD
- Consider the class of antipsychotics and the challenges associated with using this class of medications in the Long-Term Care setting
Featuring
Amie Blaszczyk, Pharm.D., BCGP, BCPS, FASCP
Long Term Care Medical Science Liaison
Amie Blaszczyk, Pharm.D., BCGP, BCPS, FASCP is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
US.CORP.X.23.00527 / US.PSY.D.24.00001Related Events
Registration
Related Resources
-
The Art of Clinical Assessment: Identifying Symptoms of Mania & Depression
Podcast May 3, 2025In this podcast, Dr Joseph Goldberg and Dr. John Meyers explore ways of interviewing patients with bipolar disorder to identify symptoms of mania and depression.
-
The Art of Clinical Assessment: Mixed Features & Mixed States
Podcast May 3, 2025In this podcast, Dr. Roger McIntyre reviews the history of mixed states and mixed features, focusing on conceptualization, phenomenology, diagnostic considerations and treatment options.
-
Digital Dialogue Series Part 5
Interview May 1, 2025As the digital healthcare landscape rapidly evolves, continuous learning will help us adapt to this trend. Digital Therapeutics are health software that treat or alleviate a condition by generating and…
Join today for instant access to all PsychU content, events, and more!
Membership is free!
"*" indicates required fields
Join PsychU Today to receive a wide array of tools and benefits
- Join our multidisciplinary community that is improving mental health care… together
- Quickly learn more about the topics you're interested in
- Access an award-winning library of on-demand mental health resources
- Gain key insights from industry expert & thought leaders
Stay Connected: